1.Hearing loss prevalence and burden of disease in China: Findings from provincial-level analysis.
Yu WANG ; Yang XIE ; Minghao WANG ; Mengdan ZHAO ; Rui GONG ; Ying XIN ; Jia KE ; Ke ZHANG ; Shaoxing ZHANG ; Chen DU ; Qingchuan DUAN ; Fang WANG ; Tao PAN ; Furong MA ; Xiangyang HU
Chinese Medical Journal 2025;138(1):41-48
BACKGROUND:
Without timely and effective rehabilitation, hearing loss may profoundly affect human life quality. China has a large population of hearing-impaired individuals, which imposes a heavy health burden on society. Moreover, this population is projected to increase rapidly owing to China's aging society.
METHODS:
We used data from a population-representative epidemiological investigation of hearing loss and ear diseases in four Chinese provinces. We estimated the national prevalence using multiple linear regression of the age-group proportions and prevalence in 31 provinces with clustering analysis. We used years lived with disability (YLDs) to analyze the disease burden and forecasted the prevalence of hearing loss by 2060 in China.
RESULTS:
An estimated 115 million people had moderate-to-complete hearing loss in 2015 across the 31 provinces of China (8.4% of 1.37 billion people). Of these, 85.7% were older than age 50 years (99 million people) and 2.4% were younger than 20 years old (2.8 million people). Of all YLDs attributable to hearing loss, 68.9% were attributable to moderate-to-complete cases. By 2060, a projected 242 million people in China will have moderate-to-complete hearing loss, a 110.0% increase from 2015.
CONCLUSIONS
The hearing loss prevalence in China is high. Population aging and socioeconomic factors substantially affect the prevalence and severity of hearing loss and the disease burden. The prevalence and severity of hearing loss are unevenly distributed across different provinces. Future public health policies should take these trends and regional variations into account.
Humans
;
China/epidemiology*
;
Hearing Loss/epidemiology*
;
Prevalence
;
Middle Aged
;
Male
;
Female
;
Adult
;
Aged
;
Adolescent
;
Young Adult
;
Child
;
Child, Preschool
;
Infant
;
Aged, 80 and over
;
Cost of Illness
2.Screen of FDA-approved drug library identifies vitamin K as anti-ferroptotic drug for osteoarthritis therapy through Gas6.
Yifeng SHI ; Sunlong LI ; Shuhao ZHANG ; Caiyu YU ; Jiansen MIAO ; Shu YANG ; Yan CHEN ; Yuxuan ZHU ; Xiaoxiao HUANG ; Chencheng ZHOU ; Hongwei OUYANG ; Xiaolei ZHANG ; Xiangyang WANG
Journal of Pharmaceutical Analysis 2025;15(5):101092-101092
Ferroptosis of chondrocytes is a significant contributor to osteoarthritis (OA), for which there is still a lack of safe and effective therapeutic drugs targeting ferroptosis. Here, we screen for anti-ferroptotic drugs in Food and Drug Administration (FDA)-approved drug library via a high-throughput manner in chondrocytes. We identified a group of FDA-approved anti-ferroptotic drugs, among which vitamin K showed the most powerful protective effect. Further study demonstrated that vitamin K effectively inhibited ferroptosis and alleviated the extracellular matrix (ECM) degradation in chondrocytes. Intra-articular injection of vitamin K inhibited ferroptosis and alleviated OA phenotype in destabilization of the medial meniscus (DMM) mouse model. Mechanistically, transcriptome sequencing and knockdown experiments revealed that the anti-ferroptotic effects of vitamin K depended on growth arrest-specific 6 (Gas6). Furthermore, exogenous expression of Gas6 was found to inhibit ferroptosis through the AXL receptor tyrosine kinase (AXL)/phosphatidylinositol 3-kinase (PI3K)/AKT serine/threonine kinase (AKT) axis. Together, we demonstrate that vitamin K inhibits ferroptosis and alleviates OA progression via enhancing Gas6 expression and its downstream pathway of AXL/PI3K/AKT axis, indicating vitamin K as well as Gas6 to serve as a potential therapeutic target for OA and other ferroptosis-related diseases.
3.Expression and clinical application of serum cystatin C and high-density lipoprotein cholesterol in AD and VD patients
Xiangyang JIANG ; Xieli YU ; Chunmei LÜ
Chinese Journal of Geriatric Heart Brain and Vessel Diseases 2024;26(3):301-304
Objective To investigate the expression of cystatin C(Cys C)and high-density lipopro-tein cholesterol(HDL-C)in the serum of patients with Alzheimer's disease(AD)and vascular dementia(VD),and their clinical application.Methods A total of 40 AD patients(AD group)and 40 VD patients(VD group)admitted to Jinhua Second Hospital from January 2020 to January 2022 were enrolled,and another 40 healthy individuals who taking physical examination in the hospital during the same period were subjected as control group.According to Montreal Cognitive Assessment Scale(MoCA)score,the AD patients were divided into mild(22 cases)and moderate to severe(18 cases)AD groups,and the VD patients were into mild(MoCA score 18-26,24 cases)and moderate to severe(MoCA score<17,16 cases)VD group.Serum levels of Cys C and HDL-C were detected in all the participants,and the diagnostic efficacy of serum Cys C and HDL-C level for AD and VD was analyzed with ROC curve analysis.Results The serum levels of TC,TG,LDL-C and Cys C were significantly higher,and that of HDL-C was obviously lower in the AD and VD groups than the control group(P<0.05).The Cys C level in the moderate to severe AD group and the moderate to severe VD group was higher than that in the mild AD group and the mild VD group(P<0.05).There was no significant difference in HDL-C level among moder-ate to severe AD group,moderate to severe VD group,mild AD group and mild VD group(P>0.05).The AUC value for the combined Cvs C and HDL-C for diagnosis of AD and VD were 0.980(95%CI:0.943-1.000)and 0.951(95%CI:0.905-0.996),respectively.Conclusion Detec-ting serum Cys C and HDL-C levels is simple and convenient.There are significant differences in their serum levels in the patients with AD and VD when compared with healthy population,which may become reference indicators for screening AD and VD.
4.Multimodal image fusion-assisted endoscopic evacuation of spontaneous intracerebral hemorrhage
Chao ZHANG ; Juan LI ; Ping-Li WANG ; Hua-Yun CHEN ; Yu-Hang ZHAO ; Ning WANG ; Zhi-Tao ZHANG ; Yan-Wei DANG ; Hong-Quan WANG ; Jun WANG ; Chu-Hua FU
Chinese Journal of Traumatology 2024;27(6):340-347
Purpose::Although traditional craniotomy (TC) surgery has failed to show benefits for the functional outcome of intracerebral hemorrhage (ICH). However, a minimally invasive hematoma removal plan to avoid white matter fiber damage may be a safer and more feasible surgical approach, which may improve the prognosis of ICH. We conducted a historical cohort study on the use of multimodal image fusion-assisted neuroendoscopic surgery (MINS) for the treatment of ICH, and compared its safety and effectiveness with traditional methods.Methods::This is a historical cohort study involving 241 patients with cerebral hemorrhage. Divided into MINS group and TC group based on surgical methods. Multimodal images (CT skull, CT angiography, and white matter fiber of MRI diffusion-tensor imaging) were fused into 3 dimensional images for preoperative planning and intraoperative guidance of endoscopic hematoma removal in the MINS group. Clinical features, operative efficiency, perioperative complications, and prognoses between 2 groups were compared. Normally distributed data were analyzed using t-test of 2 independent samples, Nonnormally distributed data were compared using the Kruskal-Wallis test. Meanwhile categorical data were analyzed via the Chi-square test or Fisher’s exact test. All statistical tests were two-sided, and p < 0.05 was considered statistically significant. Results::A total of 42 patients with ICH were enrolled, who underwent TC surgery or MINS. Patients who underwent MINS had shorter operative time ( p < 0.001), less blood loss ( p < 0.001), better hematoma evacuation ( p =0.003), and a shorter stay in the intensive care unit ( p =0.002) than patients who underwent TC. Based on clinical characteristics and analysis of perioperative complications, there is no significant difference between the 2 surgical methods. Modified Rankin scale scores at 180 days were better in the MINS than in the TC group ( p =0.014). Conclusions::Compared with TC for the treatment of ICH, MINS is safer and more efficient in cleaning ICH, which improved the prognosis of the patients. In the future, a larger sample size clinical trial will be needed to evaluate its efficacy.
5.Rational Dose of Dachengqi Decoction (大承气汤) in the Treatment of Primary and Non-primary Acute Intestinal Obstruction:A Randomize-controlled,Double-Blinded,Multicentered Clinical Trial
Xuedong AN ; Nan ZHANG ; Liyun DUAN ; Xiangyang YU ; Zhenli ZHOU ; Fengmei LIAN ; Naiqiang CUI ; Xiaolin TONG
Journal of Traditional Chinese Medicine 2024;65(21):2217-2224
ObjectiveTo determine the optimal dose of Dachengqi Decoction (大承气汤, DCQD) for the treatment of acute intestinal obstruction (AIO) through a randomized, double-blind, dosage parallel controlled, multi-center clinical trial, and to providee evidence support for the reasonable dosage of DCQD in clinical practice. MethodsBased on the commonly used clinical dose of DCQD, three different groups were set up, including low-dose group which used Dahuang (Radix et Rhizoma Rhei) 12 g, Houpo (Cortex Magnoliae Officinalis) 9 g, Zhishi (Fructus Aurantii Immaturus) 9 g, and Mangxiao (Natrii Sulfas) 4.5 g, medium-dose group using Dahuang 36 g, Houpo 27 g, Zhishi 27 g, Mangxiao 13.5 g, and high-dose group using Dahuang 60 g, Houp0 45 g, Zhishi 45 g and Mangxiao 22.5 g. Initially, 149 AIO patients with Yangming (阳明) bowel excess syndrome were randomly assigned to three groups using a stratified randomization method, and both the patients and the doctors were blinded. In addition to conventional western medicine treatment, each group was given 12 bags of granules made from the raw herbs of DCQD at different doses, taken orally or injected through a gastric catheter once every 6 hours, 3 bags each time, for 3 consecutive days. After treatment, the indicators of the three groups of patients with primary AIO and non-primary AIO were evaluated respectively, and the full analysis set (FAS) and per-protocol set (PPS) were used for analysis. The primary outcomes were the time to recover voluntary bowel movements and voluntary flatulence. The secondary outcomes were the ideal rate of spontaneous defecation and the ideal rate of spontaneous flatus. The occurrence of adverse events during the study was recorded and analyzed using the safety analysis set (SS). ResultsA total of 91 patients with primary AIO and 58 patients with non-primary AIO were included in the FAS and SS analysis, while 80 primary AIO patients and 56 non-primary AIO patients were included in the PPS analysis. Both FAS and PPS analysis showed significant differences in the time to recover voluntary bowel movements and voluntary flatulence among primary AIO patients in different dose groups of DCQD (P<0.01), and the high- and medium-dose groups assumed less time than the low-dose group (P<0.05). There was no statistically significant difference in the ideal rate of spontaneous defecation and spontaneous flatus among the three groups (P>0.05). And consistent results were seen in the non-primary AIO patients among the three groups. Five adverse events occurred in primary AIO patients (3 in the low-dose group, 1 in the medium-dose group, and 1 in the high-dose group), mainly manifested as abdominal distension and abdominal pain, and there was no statistically significant difference in the incidence of adverse events (P>0.05). No adverse events occurred in patients with non-primary AIO. ConclusionDCQD, as an effective treatment for patients with AIO, is commonly used at a medium dose for patients with primary AIO and at a high dose for patients with non-primary AIO. The therapeutic advantage is mainly reflected in the shorter time to recover spontaneous defecation and spontaneous flatulence and the improvement of intestinal function.
6.Research on the role of resveratrol against breast cancer
Qingdong GAO ; Xufang DUAN ; Yan LI ; Tao XU ; Yangyang YU ; Guodong BAI
China Pharmacy 2024;35(11):1408-1412
Breast cancer (BC) ranks first in the incidence rate of female malignant tumor, the notable features of which include high invasive behavior, high malignant degree and poor prognosis. Resveratrol, a plant antioxidant, has been identified as a potential therapeutic agent for the occurrence and progress of BC. This article explores the mechanism of resveratrol intervention in BC by evaluating several in vitro and in vivo studies. It was found that resveratrol can weaken the proliferation and survival ability of BC cells, suppress their growth, metastasis, and invasion, and reverse their resistance to adriamycin by promoting cell apoptosis, regulating autophagy, inhibiting glycolysis and regulating the tumor microenvironment, expressions of matrix metalloproteinases, epithelial-mesenchymal transition and drug-resistant proteins, etc. The limited number of clinical trial studies on resveratrol, mainly focusing on prevention effect of it on breast cancer, may be one of the reasons that affect the comprehensive evaluation of the anti-cancer efficacy of resveratrol.
7.Research on the role of resveratrol against breast cancer
Qingdong GAO ; Xufang DUAN ; Yan LI ; Tao XU ; Yangyang YU ; Guodong BAI
China Pharmacy 2024;35(11):1408-1412
Breast cancer (BC) ranks first in the incidence rate of female malignant tumor, the notable features of which include high invasive behavior, high malignant degree and poor prognosis. Resveratrol, a plant antioxidant, has been identified as a potential therapeutic agent for the occurrence and progress of BC. This article explores the mechanism of resveratrol intervention in BC by evaluating several in vitro and in vivo studies. It was found that resveratrol can weaken the proliferation and survival ability of BC cells, suppress their growth, metastasis, and invasion, and reverse their resistance to adriamycin by promoting cell apoptosis, regulating autophagy, inhibiting glycolysis and regulating the tumor microenvironment, expressions of matrix metalloproteinases, epithelial-mesenchymal transition and drug-resistant proteins, etc. The limited number of clinical trial studies on resveratrol, mainly focusing on prevention effect of it on breast cancer, may be one of the reasons that affect the comprehensive evaluation of the anti-cancer efficacy of resveratrol.
8.Expression of S100A7A in gastric cancer and its effect on proliferation and metastasis
Wushuang XIAO ; Linjie HONG ; Zhen YU ; Ping YANG ; Jieming ZHANG ; Siyang PENG ; Xiangyang WEI ; Yidong CHEN ; Side LIU ; Jide WANG
The Journal of Practical Medicine 2024;40(10):1344-1350
Objective The objective of this study is to examine the expression level of the S100A7A protein in both gastric cancer tissues and cells,as well as to evaluate its impact on the malignant phenotype of gastric cancer(GC)cells.Methods Immunohistochemical assay was used to detect the expression characteristics of S100A7A in 21 gastric cancer tissues and their corresponding paracancerous tissues,as well as to investigate its correlation with gastric cancer clinicopathological factors.Gastric cancer cells were genetically modified to overex-press S100A7A through plasmid transfection.Subsequently,the impact of S100A7A on the proliferation,migra-tion,and invasion capacities of gastric cancer cells was assessed using cell proliferation assays(EdU assay and plate cloning assay)as well as cell migration and invasion assays(Transwell assay and scratch assay).Results The expression of S100A7A protein was higher in GC tissues than in paracancerous tissues;Overexpression of S100A7A may increase gastric cancer cell proliferation,migration,and invasion.Conclusion S100A7A is a possible oncogene in GC and is predicted to serve as a new diagnostic and therapeutic target for the disease.
9.Construction of secretory IgA against SARS-CoV-2 and its biodistribution through nasal administration in mice
Ping HUANG ; Guanying ZHANG ; Xiangyang CHI ; Hancong SUN ; Ting FANG ; Changming YU ; Wei CHEN
Military Medical Sciences 2024;48(7):501-508
Objective To construct secretory IgA(sIgA)based on the previously screened IgG neutralizing antibody ZW2G10 against SARS-CoV-2,evaluate its activity and find out about the biodistribution of sIgA in ICR mice after nasal administration.Methods After expression,purification,and identification,sIgA was evaluated for its binding and neutralizing activity through ELISA and pseudovirus-based neutralization assays.SIgA was coupled with Alexa Fluor 750 dye and administered to mice via nasal administration.In vivo imaging was used to observe the biodistribution of sIgA.After dissection of the mice,the biodistribution of sIgA in various tissues and organs was observed.Results Compared with IgG,sIgA retained the binding ability to SARS-CoV-2 S proteins,and its neutralizing ability was enhanced.After nasal administration of a single dose of 1 mg/kg,sIgA could be retained in the lungs of mice for more than 72 hours.SIgA could be detected only in the nasal cavity and gastrointestinal tract within 8 h of administration,but not in the heart,liver,kidney,spleen,brain,bladder or blood.Conclusion In this study,a universal and efficient sIgA expression system has been established.sIgA can effectively target the respiratory tract and lungs after nasal administration.SIgA is expected to become a potential drug that provides immediate passive immune protection.
10.Real-time shear wave elastography combined with biochemical indicators for evaluating liver injury in patients with chronic kidney disease
Xiangyang FAN ; Yan ZHANG ; Xiao HE ; Ziwei WANG ; Jing YU
Chinese Journal of Medical Imaging Technology 2024;40(8):1221-1225
Objective To observe the value of real-time shear wave elastography(SWE)combined with biochemical indicators for evaluating liver injury in patients with chronic kidney disease(CKD).Methods Totally 210 patients with CKD(CKD group)and 64 healthy subjects(control group)were retrospectively enrolled.Patients in CKD group were further divided into CKD1-5 subgroups according to CKD stages.SWE parameters of liver and kidney,including mean value,the maximum value and the median value of Young's modulus(EQImean,EQImax and EQImed)were compared between CKD subgroups and control group.Spearman correlation analysis were performed to explore the correlations of liver and kidney SWE parameters with CKD stage,as well as of liver SWE parameters with biochemical indicators.Multivariate logistic regression analysis was used to screen independent predictors of liver injury in CKD patients.Receiver operating characteristic curves were drawn,the area under the curves(AUC)were calculated to evaluate the efficacy of the independent predictors alone and their combination for assessing liver injury in CKD patients.Results Significant differences of liver and kidney SWE parameters were found among CKD subgroups and control group(all P≤ 0.001).Pairwise comparison showed that liver SWE parameters in CKD5 subgroup and liver EQImax in CKD4 subgroup were all higher than those in control group(all P<0.003).Kidney SWE parameters in CKD3 subgroup were all higher than those in control group,while in CKD4 subgroup were all higher than those in control group and CKD1-3 subgroup(all P<0.003).Kidney EQImean and EQImed in CKD5 subgroup were all higher than those in control group and CKD1-4 subgroup,while kidney EQImax in CKD5 subgroup were higher than those in control group and CKD1-3 subgroup(all P<0.003).Liver and kidney SWE parameters were lowly-moderately and positively correlated with CKD stages(r=0.364-0.665,all P<0.001).Liver SWE parameters of CKD were weakly and positively correlated with alkaline phosphatase(ALP)(r=0.229-0.248,all P<0.01).The γ-glutamyl transferase,ALP and liver EQImax were all independent predictors of liver injury in CKD patients(all P<0.01),with AUC for evaluating liver injury in CKD patients alone of 0.645,0.756 and 0.741,respectively,lower than that of their combination(0.851,all P<0.01).Conclusion Real-time SWE combined with liver function indicators could reflect degree of liver injury in patients with different CKD stages.

Result Analysis
Print
Save
E-mail